InnoCare Pharma Limited (SHA:688428)

Market Cap	26.58B
Revenue (ttm)	1.43B
Net Income (ttm)	-229.64M
Shares Out	n/a
EPS (ttm)	-0.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,449,416
Average Volume	7,394,034
Open	25.39
Previous Close	25.17
Day's Range	24.41 - 25.72
52-Week Range	10.65 - 34.02
Beta	0.73
RSI	54.69
Earnings Date	Nov 13, 2025

About InnoCare Pharma

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 939
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688428

Financial Performance

In 2024, InnoCare Pharma's revenue was 1.01 billion, an increase of 36.68% compared to the previous year's 738.54 million. Losses were -440.63 million, -30.20% less than in 2023.